The first new class of antidepressant drugs in more than three decades was approved in March when the U.S. Food and Drug Administration (FDA) fast-tracked esketamine, the chemical cousin of illegal street drug ketamine, to prescribe to patients with treatment-resistant depression.
Developed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, esketamine is marketed under the name Spravato and dispensed as a nasal spray administered under the supervision of trained health care professionals.
Ketamine is the chemical mixture of esketamine and arketamine, two mirror-image molecules. But when the molecules are separated, esketamine has been shown to be more potent. As a result, it requires a lower dosage and has a decreased risk of disassociation, tolerance and abuse.
“That’s why Janssen preferred to develop esketamine. It has more robust antidepressant efficacy with less side effects,” said Rodrigo Machado-Vieira, M.D., Ph.D., professor of psychiatry and behavioral sciences and director of the Experimental Therapeutics and Molecular Pathophysiology Program at UTHealth Harris County Psychiatric Center. “It’s the most striking discovery in psychiatry in the past 34 years at least, so I’m very excited.”
Treatment-resistant depression is common and there is a clear unmet need for fast-acting therapeutics.
More than 16 million adults in the U.S. are affected by depression. While a variety of antidepressant medications help people, such as Prozac and Cymbalta, about one-third of patients don’t respond to treatment.
“There’s simply a dearth of options for patients in this refractory, treatmentresistant population,” said Sanjay Mathew, M.D., vice chair for research and professor in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine. “Many patients cycle in and out of numerous … first- and second-line antidepressant agents, but [esketamine] will offer something that’s evidence-based and on-label for this more ill and difficult-to-treat population.”
Spravato is for patients who have tried but do not respond to at least two antidepressants. While all the other antidepressants on the market take two to three weeks to take effect, esketamine and ketamine work in a matter of hours.
“Patients don’t need to wait too long to have efficacy with these drugs,” said Machado- Vieira, who led a clinical trial on the rapid anti-suicidal effects of ketamine in depression and alcohol abuse. “It improves symptoms in a wide range of patients who do not respond to any standard treatment.”
Still, the FDA requires anyone using Spravato to take a traditional oral antidepressant, as well.
Esketamine’s long-term safety is not fully understood.
Janssen conducted five Phase 3 studies in patients with refractory depression: three short-term studies, one maintenance of effect study and a long-term safety study that showed the esketamine nasal spray provided a “statistically significant, clinically meaningful, rapid, and sustained improvement of depressive symptoms.”
While the company maintains the drug is “generally tolerable” for extended use, some experts think more research needs to be done.
“I think there are a few gaps that need to be filled in terms of finding out the number of applications, how safe it is in the long term,” Machado-Vieira said.
Ketamine was approved by the FDA in 1970 as a potent anesthetic for diagnostic and surgical procedures, but it wasn’t until recently that clinics across the country started offering ketamine infusions to treat pain and depression.
“Since it was [working] so fast, many clinics started providing off-label ketamine for patients with depression,” Machado-Vieira said. “No one with depression, especially treatment-resistant depression, would like to wait two to three weeks to have the medication kick in— especially in the first week of treatment with standard antidepressants when patients are at much higher risk for suicidal attempts.”
Prepare for sticker shock.
Because ketamine has not been approved by the FDA to treat depression, infusions aren’t covered by insurance and can be costly.
In Houston, patients pay out-of-pocket anywhere from $500 to $1,350 per ketamine infusion. Spravato ranges from $590 to $885 per treatment session. The first month’s induction phase consists of two treatments per week. After that, patients move into maintenance, during which they receive one treatment every week or every other week.
Because Spravato has been approved by the FDA, it’s important to note the list prices don’t include insurance coverage, rebates or discounts.
“It’s something we’ve all been waiting for,” Mathew said.
Veterans find peace through camaraderie https://t.co/6KB4epx2md via @newsandtribune
By targeting the MFAP5 protein, our researchers found they were able to reduce fibrosis in #ovariancancer and #pancreaticcancer, and improve the effectiveness of #chemotherapy: https://t.co/l3O6inEWZH @CancerFrontline #endcancer https://t.co/z4NZnIff0C
.@garciamanero on our #MDS #CancerMoonshot: “We’ve gone from a nihilistic view of this disease to a very positive and optimistic approach.” #endcancer https://t.co/sY7IsBpoHF
#VAResearchNewsBrief: Diet quality affects gut microbiome. Patients who eat a good-quality diet have higher levels of beneficial bacteria, those eating a poor-quality diet may have more harmful bacteria, found a @VAHouston study #VAResearch @VeteransHealth https://t.co/K3UufOjMhm https://t.co/OVEzNQGt9m
Dr. Raymond Grogan sits down with the Annals of Thyroid about his research, and scarless thyroid surgery in their latest issue. https://t.co/Y7fWozy6Cz #thyroidsurgery
Shreela Sharma, PhD, RD, of @UTexasSPH discusses the health benefits of milk: https://t.co/7y66ySuw8Y
RT @UTexasSPH: MD/MPH student Anisha Somani is the winner of @apha’s 2019 Excellence in Public Health Award. Somani’s work ranges from the…
RT @jvalenza: Today may be National Tooth Fairy Day but we celebrated yesterday with not one but two fairies visiting our special little pa…
DYK that we were one of the first three cancer institutions to receive the comprehensive cancer center designation from @theNCI? Learn now this funding has supported our work to #endcancer since 1971: https://t.co/FYMzt8Ldcx
Today on the blog, Dr. Christina Treece discusses what can cause postpartum obsessive compulsive disorder (OCD), how it's diagnosed and more: https://t.co/YV0nk33lRn
USF Health working with VA to train providers how to care for Women Veterans https://t.co/a3tCH3hhFq via @wusf
RT @RiceAthletics: 📱 TAKEOVER ALERT 📱@RiceSoccer student athlete @madiisonkent is taking you behind the scenes today as they prepare for…
RT @CPRITTexas: Congrats to @bcmhouston’s @SeragHashem on his recent CPRIT Liver Cancer CAP award. In 2017 he discussed the value of CPRIT…
RT @DrPaulKlotman: Great opportunity today at Harvey Symposium to honor Mayor Sylvester Turner and former County Judge Ed Emmett for their…
Dr. Laurel L. Williams, Chief of Psychiatry at @TexasChildrens, shares how schools can better prepare families for the mental health impact active shooter drills can have on students. Learn more via @KHOU: https://t.co/beRvrBXvdf